

Sanket U. Shah, MD – Biography

Sanket U. Shah, M.D. is a board certified Ophthalmologist with a specialization in medical and surgical diseases of the retina and the vitreous. He received his medical degree from the Seth G. S. Medical College and King Edward Memorial Hospital in Mumbai, India. He spent two years pursuing a research fellowship in ocular oncology at the Wills Eye Hospital in Philadelphia, PA; and a second research fellowship in retina at the Jules Stein Eye Institute at UCLA in Los Angeles, CA. His training includes an internship in internal medicine at the Albert Einstein College of Medicine - Jacobi Medical Center in Bronx, NY, followed by residency in Ophthalmology at the Indiana University School of Medicine in Indianapolis, IN, where he served as the chief resident and received several awards. He then completed his fellowship training in vitreoretinal surgery and medical diseases of the retina at the prestigious Jules Stein Eye Institute at UCLA in Los Angeles, CA.

Dr. Shah is Board certified by the American Board of Ophthalmology. He is a member of the American Academy of Ophthalmology and the American Society of Retina Specialists. He has served as a co-investigator on several national clinical trials and participated in numerous research projects spanning topics including diabetic retinopathy, vitreoretinal interface abnormalities, macular degeneration, automated retinal image analysis, optical coherence tomography, uveal melanoma, and retinoblastoma. He has received the National Eye Institute travel grant to present his research. He has over 35 peer-reviewed publications in national and international journals, 1 book chapter, and several abstracts, oral, video and poster presentations to his credit. He has served as a reviewer for articles in peer-reviewed journals such as Ophthalmology and the American Journal of Ophthalmology.

Research and publications:

Selected Clinical Trials (Co-investigator)

1. A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
2. Phase II and Phase III Multicenter Randomized Clinical Trials of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)
3. A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration
4. Long Term Follow Up to Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human

Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients with Advanced Age-Related Macular Degeneration (AMD)

5. A Phase 2B Randomized Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) compared to Sham in Subjects with Autosomal Recessive Stargardt Disease.

Book chapter

1. Hubschman JP, Shah SU, Voleti V. The future of vitrectomy. In: Sebag J, ed. *Vitreous in Health and Disease*. New York, NY: Springer; 2014:699-712.

Selected peer-reviewed publications

1. Shah SU, Maturi RK. Therapeutic options in refractory diabetic macular oedema. *Drugs*. 2017;77(5):481-492.
2. Shah SU, Harless A, Bleau L, Maturi RK. Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema. *Retina*. 2016;36(10):1986-96.
3. Amouyal F, Shah SU, Pan CK, Schwartz SD, Hubschman JP. Morphologic features and evolution of inner retinal dimples on optical coherence tomography after internal limiting membrane peeling. *Retina*. 2014;34(10):2096-102.
4. Shah SU, Mashayekhi A, Shields CL, Walia HS, Hubbard GB, Zhang J, Shields JA. Uveal metastasis from lung cancer: Clinical features, treatment and outcome in 194 patients. *Ophthalmology*. 2014;121(1):352-7.
5. Shah SU, Shields CL, Bianciotto CG, Iturralde J, Al-Dahmash SA, Say EA, Badal J, Mashayekhi A, Shields JA. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. *Ophthalmology*. 2014;121(1):269-75.
6. Zutis K, Trucco E, Hubschman JP, Reed D, Shah S, van Hemert J. Towards automatic detection of abnormal retinal capillaries in ultra-widefield-of-view retinal angiographic exams. *Conf Proc IEEE Eng Med Biol Soc*. 2013;2013:7372-5.
7. Shah SU, Koenig MJ, Dacquay Y, Mozayan A, Hubschman JP. Assessment of the risk of needlestick injuries associated with intravitreal injections. *Retina*. 2014;34(4):781-4.
8. Shah SU, Pilli S, Telander DG, Morse LS, Park SS. Survey of patients with age-related macular degeneration: knowledge and adherence to recommendations. *Can J Ophthalmol*. 2013;48(3):204-9.
9. Say EA, Shah SU, Ferenczy S, Shields CL. Optical coherence tomography of retinal and choroidal tumors. *J Ophthalmol*. 2012;2012:385058.
10. Shah SU, Kaliki S, Shields CL, Ferenczy S, Harmon S, Shields JA. Enhanced depth imaging optical coherence tomography of choroidal nevus in 104 cases. *Ophthalmology*. 2012;119(5):1066-72.
11. Shields CL, Kaliki S, Shah SU, Bianciotto CG, Jabbour P, Shields JA. Effect of intra-arterial chemotherapy on retinoblastoma- induced retinal detachment. *Retina*. 2012;32(4):799-804.

12. Shah SU, Seibles JoAnn, Park SS. Photographic diabetic retinopathy screening in an urban family practice clinic: effect on compliance to eye exam. *Ophthalmic Surg Lasers Imaging*. 2011;42(5):383-9.
13. Shah SU, Kerkar SP, Pazare AR. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a tertiary care hospital in western India. *Br J Ophthalmol*. 2009;93(1):88-90.

Complete list of clinical trials, publications and meeting poster/oral presentations available upon request

Honors & Awards:

- Sir J.R.D. Tata and Ratan Tata scholarships during medical school (2006, 2008, 2009)
- Indian Council of Medical Research studentship awards (2007, 2008)
- Award for the best article on EyeWiki in the Retina and Vitreous category titled Vitreomacular Traction Syndrome (2013)
- Best Resident Research Paper Award, Indiana University Department of Ophthalmology (2015)
- Merrill Grayson Leadership Award, Indiana University Department of Ophthalmology (2016)
- David May II Fellowship Award, UCLA Stein Eye Institute (2016)
- Abe Meyer Memorial Fellowship Award, UCLA Stein Eye Institute (2017)

Hospital Affiliations:

- Community Memorial Hospital, Ventura
- Ventura County Medical Center, Ventura
- Los Robles Hospital and Medical Center, Thousand Oaks

Services Dr. Shah provides include management of:

- Retinal vein occlusion, Retinal tears and holes,
- Retinal detachment, Retinal dystrophy & degeneration
- Vitreous hemorrhage
- Macular hole, Macular pucker (Epiretinal membrane)
- Macular degeneration
- Diabetic retinopathy
- Dislocated lens
- Aphakia
- Uveitis

Dr. Shah speaks conversational Spanish, and is fluent in Hindi, Gujarati, and Marathi.